Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Posted by Teresa Graham on Jul 31st, 2026

Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$16.57 and traded as high as C$16.66. Cipher Pharmaceuticals shares last traded at C$16.46, with a volume of 26,094 shares traded.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$17.00 price objective on shares of Cipher Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of C$17.00.

View Our Latest Stock Analysis on CPH

Cipher Pharmaceuticals Stock Up 0.6%

The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of C$16.57 and a two-hundred day moving average price of C$16.50. The company has a market capitalization of C$417.94 million, a P/E ratio of 13.83 and a beta of 1.15.

Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last posted its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The company had revenue of C$17.39 million for the quarter. Equities research analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

(Get Free Report)

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.